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Abstract 
Background 
Urinary incontinence (UI) is common immediately after prostate surgery.  Men are often 
advised to perform pelvic floor exercises, but evidence to support this is inconclusive.  The 
Men After Prostate Surgery (MAPS) study consisted of two randomised controlled trials 
testing whether formal one-to-one pelvic floor muscle training reduces incontinence.   
Methods 
Men who were incontinent six weeks after radical prostatectomy (Trial 1) or transurethral 
resection of the prostate (TURP, Trial 2) were randomly assigned, using remote computer 
allocation, to four sessions with a Therapist over three months (intervention group, N=205, 
220 respectively), or standard care and lifestyle advice only (control group, N=206, 222).  
The primary endpoints, collected via postal questionnaires, were participants’ report of UI, 
and incremental cost per quality-adjusted life year (QALY) after 12 months.  Outcome 
assessors were blinded to group assignment, but this was not possible for participants or 
caregivers.  Recruitment was completed in September 2008.   
Findings 
In the intervention group in Trial 1 (radical prostatectomy), the UI rate at 12 months was not 
significantly different compared with the control group:  75.5% (148/196, intervention) versus 
77.4% (151/195, control):  absolute risk difference (RD) -1.9% [-10% to 6%].   
In Trial 2 (TURP), the difference in the UI rate at 12 months was not statistically significant:  
126/194, 64.9% in the intervention group versus 125/203, 61.5% in the control group, RD 
3.4% [-6% to 13%].  Adjusting for minimisation factors or performing ‘treatment received’ 
analyses did not change these results in either trial.  No adverse effects were reported.   
In both trials, the intervention resulted in higher mean costs per patient (£180 and £209 
respectively) but there was no evidence of an economically important difference in QALYs 
(differences: 0.002 and 0.00003).   
Interpretation 
In settings where information about pelvic floor exercise is currently widely available, one-to-
one conservative physical therapy for men who are incontinent after prostate surgery is 
unlikely to be effective or cost-effective.  The high rates of persisting incontinence after one 
year indicate a significant level of unrecognised and unmet need for management amongst 
these men.   
 
Clinical Trial registration number:   ISRCTN87696430 
 
Funding  
National Institute of Health Research, Health Technology Assessment (NIHR HTA) 
Programme.   
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Background 
 
Radical prostatectomy (RP) is a key treatment in localised (early stage) prostate cancer and 
may be performed by open surgical approaches (retropubic or less frequently, perineal) or 
by minimally invasive techniques using laparoscopic or robotic technologies.  Men with lower 
urinary tract symptoms secondary to benign prostatic enlargement (BPE) who fail to respond 
to medical therapy are treated surgically by transurethral resection of the prostate (TURP).  
Although newer technologies continue to emerge, TURP remains the standard and most 
cost effective approach.(1-3)   
 
Both groups of men are at risk of post-operative urinary incontinence (UI).  Radical 
prostatectomy is associated with high rates, recently reported at around 16% at one year 
following surgery.(4;5)  TURP for BPE is associated with a much lower prevalence of 
incontinence, 9% initially(1) and around 1% at 12 months postoperatively,(6) but as the 
operation is performed much more frequently, this still presents a significant public health 
burden.   
 
Effectiveness of pelvic floor muscle training (PFMT) in women is relatively well established. 
(7;8)  Analogous advice to perform pelvic floor muscle exercises is a typical early 
management strategy for men with stress UI after prostatectomy, but successive updates of 
Cochrane reviews concluded that there was insufficient evidence to demonstrate its 
effectiveness and hence cost-effectiveness.(9)  Men who undergo TURP more often have 
overactive bladder syndrome or urgency urinary incontinence:  bladder training (BT) is often 
recommended for these conditions, again without clear evidence of efficacy.(10)   
 
The Men After Prostate Surgery (MAPS) trial was designed to compare a structured PFMT 
program with BT if indicated delivered in four one-to-one sessions, with current care that 
does not include formally taught PFMT.  The primary outcome was UI reported by men at 12 
months after randomisation.   
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Methods 
 
Study Design 
Men having prostate surgery were identified in 34 centres in the United Kingdom (UK) and 
invited to receive a screening questionnaire three weeks after surgery.  Those who reported 
UI in their ‘Screening’ questionnaire were invited to be randomised.  However, formal trial 
entry was limited to those men who were still incontinent as judged by their response to a 
further ‘Baseline’ questionnaire. This second questionnaire also contributed wider descriptive 
data as reported in Table 1. The methods were identical in the two parallel but separate trials 
(Trial 1 after radical prostatectomy and Trial 2 after TURP for BPE).   
 
Randomisation was by remote computer allocation using the randomisation service of the 
Centre for Healthcare Randomised Trials (CHaRT, Health Services Research Unit, 
University of Aberdeen).  Allocation was minimised based on centre, age and pre-existing 
UI.  The process was independent of all clinical collaborators.   
 
Participants and therapists could not be masked to the intervention.  Outcome assessment 
was by participant-completed questionnaires and diaries, and data were entered by clerical 
staff blinded to group allocation.   
 
Participants 
Men were eligible if they had UI at six weeks after surgery for either prostate cancer or BPE.  
Incontinence was defined as any positive response to either of two screening questions from 
the International Consultation on Incontinence Questionnaire Urinary Incontinence Short 
Form (ICIQ-UI SF) questionnaire.(11)  Participants needed to be able to comply with the 
intervention and complete study questionnaires.  Men were excluded if they had been 
referred for or received formal PFMT.  Men who had TURP for lower urinary tract symptoms 
secondary to advanced prostate cancer (‘channel TURP’) or were to receive radiotherapy 
were excluded as these factors might independently affect bladder function or continence 
mechanisms.   
 
Interventions 
All randomised men received a Lifestyle Advice Leaflet that described the influence of fluid 
intake, caffeine, diet, constipation, fitness, lifting, chest problems and urinary tract infections 
on continence.  No information was provided in the leaflet about pelvic floor exercises or 
techniques for dealing with urgency symptoms.  Men having radical prostatectomy are 
commonly told about pelvic floor exercises by health care professionals and information is 
also widely available in the public domain, for example through the internet.  No attempt was 
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made to prevent any participants from accessing such information independently, or from 
leaflets if these were part of standard care.   
 
Men randomised to the intervention groups were invited to attend four one-to-one sessions 
held over a period of three months with a therapist and received a supplementary MAPS 
Pelvic Floor Exercise leaflet, aimed at establishing a home exercise regimen.  The therapists 
were either specialist continence physiotherapists or specialist continence or urology nurses.  
Therapists were provided with standardised training in the management of male UI based on 
PFMT and BT.  Details of the intervention and its rationale are described elsewhere.(12)  
Men in the control groups were not invited to one-to-one therapy and did not receive the 
MAPS Pelvic Floor Exercise leaflet. 
 
Outcome measurements 
The primary clinical endpoint was men’s report of UI at 12 months after randomisation using 
the ICIQ-UI SF, a simple validated patient-completed instrument.(11)  Incontinence was 
defined as any positive response to either of two screening questions from the ICIQ-UI SF 
questionnaire:(11) ‘how often do you leak urine?’ and ‘how much urine do you leak?  The 
primary measure of cost-effectiveness was incremental cost per quality-adjusted life year 
(QALY).  Data at trial entry were collected by postal questionnaires and a 3-day urinary 
diary, and outcome data were collected by postal questionnaire and diary at 3, 6, 9 and 12 
months after randomisation.   
 
Data collected included:  urinary outcomes (using the ICIQ-UI SF which measures frequency 
and severity of incontinence, the effect of incontinence on quality of life as a composite ICIQ 
score, the presence and type of incontinence)(11); use of pads and catheters; daytime and 
night time urinary frequency and incontinence; quality of life (EQ-5D and SF-12); use of 
health services in both primary and secondary care; QALYs derived from responses to the 
EQ-5D (13); and frequency of the practice of pelvic floor exercises.  Data were also collected 
on bowel outcomes (such as faecal incontinence) and sexual function (such as erectile 
function).  Data for all other secondary outcomes will be published in a forthcoming HTA 
Monograph.   
 
Sample size and statistical analysis 
We identified that achieving a difference of 15% in incontinence rates would be of clinical 
importance.  Therefore, we aimed to identify an absolute difference between intervention 
and control groups of 15% (85% versus 70%) in the number of men who were still 
incontinent at 12 months:  174 men per arm of each trial would be needed to give 90% 
power to detect a statistically significant difference at the 5% level.  This would also allow the 
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detection of a difference equivalent to 0.30 of a standard deviation for continuous measures, 
such as quality of life, with 80% power.  Allowing for dropout after enrolment, we planned to 
recruit 200 men per arm of each trial.   
 
Descriptive statistics were tabulated reporting baseline demographics and clinical 
characteristics using means and standard deviations (SD).  We did not impute missing 
values for non-responders to questionnaires or diaries.   
 
Intention-to-treat analyses (men analysed according to randomised group) were used to 
compare the primary outcome at 12 months using general linear models adjusting for age 
and pre-existing UI and trial entry data where appropriate.  For the binary outcomes, a 
Poisson link function was used to estimate relative risks and robust standard errors were 
used to estimate the confidence intervals.(14)  A secondary comparison was conducted to 
estimate the efficacy of the treatment received using a latent variable approach (‘adjusted 
treatment received’) (15) by the method described by Nagelkerke and colleagues.(16) 
 
Planned subgroup analyses explored the effect on the primary outcome of potentially effect-
modifying factors, such as pre-surgery incontinence, type of incontinence and type of 
therapist (physiotherapy or nursing background).  Stricter levels of statistical significance 
(2P<0.01) were sought, reflecting the exploratory nature of these analyses.   
 
Economic evaluation 
The economic evaluation was a within-trial analysis at 12 months after recruitment.  Direct 
health service costs associated with each treatment were derived by combining data on use 
of health services with unit cost data extracted from the literature or from relevant 
sources(17-20) to generate the total cost for each participant.  QALYs were generated using 
the responses to the EQ-5D.   
 
Mean costs for both intervention and control groups were compared using unpaired t tests 
and linear regression adjusted for data measured at trial entry.  Non-parametric 
bootstrapping was used to estimate confidence limits.  Differences in mean QALYs were 
estimated in a similar fashion and incremental cost-effectiveness ratios calculated, where 
appropriate.   
 
Ethical approval 
This trial was approved by the Multicentre Research Ethics Committee, Edinburgh, Scotland, 
and overseen by an independent trial steering committee and a separate independent data 
monitoring committee.  All men gave signed informed consent to being screened, and 
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separately to being randomised:  the trial was conducted in accordance with the Declaration 
of Helsinki.   
 
Funding  
The trial was funded by the National Institute of Health Research, Health Technology 
Assessment (NIHR HTA) Programme (project number 03-14-03) and will be published in full 
in Health Technology Assessment.  The funder of the study had no role in study design, data 
collection, data analysis, data interpretation or writing of the report.   
 
Author information 
All authors agreed to submit the manuscript to the Lancet.  Data was accessible to CB, CR, 
MK, LV, GMcP.      
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Results 
 
Between January 2005 and September 2008, in 34 UK centres, we approached 1158 men 
having a radical prostatectomy of whom 780 met the inclusion criteria for screening and 95% 
(742/780) responded to the screening questionnaire.  We also approached 5986 men having 
a TURP: of 2838 eligible for screening, 91% (2588/2838) responded.  Of those eligible for 
randomisation at around six weeks after surgery, 87% (411/472) entered the radical 
prostatectomy RCT (Trial 1) and 86% (442/512) entered the TURP RCT (Trial 2, Figures 1A 
and 1B).  Follow up rates for the primary outcome were high (95% (391/411) in Trial 1 and 
90% (397/442) in Trial 2).  No important clinical or demographic differences were identified 
between the randomised groups at entry in either trial (Table 1).   
 
Exercise behaviour and treatment compliance 
Many men had prior knowledge of pelvic floor exercises (380/411, 92%in Trial 1 and 
183/442, 41% in Trial 2):  84% (346/411) of men in the former and 21% (93/442)  in the latter 
claimed to be performing them at six weeks after operation but before randomisation (Table 
1).  Of the men allocated to the intervention groups, 189/205 (92%) and 189/220 (86%) 
respectively attended at least one therapy visit, while 175 (85%) and 158 (72%) respectively 
attended until the final visit (Table 4, though not necessarily all four appointments).  Men in 
the intervention groups were more likely to report carrying out exercises at 12 months (Table 
2):  Trial 1: 128/191 (67%) versus 95/189 (50%), adjusted risk ratio (RR) 1.30 [95% CI 1.09 
to 1.53]; Trial 2:  122/188 (65%) versus 39/193 (20%), adjusted RR 3.20 [2.37 to 4.32].   
 
Urinary outcomes after radical prostatectomy (Trial 1) 
At 12 months, 75.5% (148/196) of the intervention group and 77.4% (151/195) of the control 
group reported some UI, absolute Risk Difference (RD) -1.9% [-10% to 6%], far short of the 
pre-specified target difference of 15% (Table 3).  Adjusting for minimisation factors or 
performing a ‘treatment received’ analysis did not change these results (Table 3).   
 
Urinary outcomes after TURP (Trial 2) 
At 12 months, 64.9% (126/194) of the intervention group and 61.6% (125/203) of the control 
group reported some UI, absolute RD 3.4% [-6% to 13%], again, far short of the pre-
specified target difference of 15% (Table 3).  Adjusting for minimisation factors or performing 
a ‘treatment received’ analysis did not change these results (Table 3).   
 
In both trials, there were no statistically significant differences in the prevalence of UI or the 
mean ICIQ score between the groups at any of the time points (Figures 2, 3), nor in any of 
the other outcomes related to urinary leakage (Table 2).  The majority of the improvement in 
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continence occurred within three months of trial entry (Figure 3).  There was no evidence of 
a difference between trial groups in effect on faecal incontinence or erectile function (data 
not shown), or in any of the pre-specified subgroups (Figure 4).   
 
Economic evaluation after radical prostatectomy (Trial 1) 
The UK NHS provides universal health care coverage with care free at the point of use.  The 
total trial-related NHS cost (interventions and subsequent NHS care) per participant was 
statistically significantly higher in the intervention group (difference estimate £181 [95% CI 
£107 to £255], US$287, [95% CI $170 to $404]).(21)   This was almost entirely due to the 
cost of the one-to-one PFMT.  On average, QALYs were virtually identical in the trial groups 
(difference: 0.002, [95% CI -0.027 to 0.023]), giving a mean incremental cost per QALY of 
£90,510 (US$143,458).   
 
Economic evaluation after TURP (Trial 2) 
The trial-related cost (interventions and the cost of subsequent NHS care) per participant 
was statistically significantly higher in the intervention group (difference estimate £209 [95% 
CI £147 to £271], US$332 [95% CI $233 to $430]) almost entirely due to the cost of PFMT.  
On average, the QALYs were lower for the intervention although not statistically significantly 
(-0.00003 [95% CI -0.026 to 0.026]).  On average the intervention was dominated because it 
was more costly and there was no evidence that it was any more effective.  
 
Adverse effects 
No adverse effects were reported by any participant in the trials.   
 
Overall incontinence rates 
At six weeks after radical prostatectomy, 59% (429/742) of men reported incontinence 
(Figure 1a).  Amongst the 411 randomised incontinent men, the rate of incontinence a year 
later, irrespective of management and assuming non-responders were dry, was 73% (299 
men incontinent, Table 2).  Of the original total population of 742 men, this translates to 40% 
(299) with any incontinence a year after radical prostatectomy (20% (152) severe, 18% (131) 
wearing pads).  As expected, the incontinence rate at trial entry six weeks following TURP 
was lower (17%: 442/2590, Figure 1b), but of the 442 randomised men, 57% (251) were still 
wet 12 months later (Table 2).  Of the original total population of 2590 men, this translates to 
10% (251/2590) still wet a year after TURP (4% (97/2590) severe, 2% (48/2590) wearing 
pads).   
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Discussion 
 
Summary of main findings 
While the provision of one-to-one PFMT for men with UI after radical prostatectomy or TURP 
increased the number of men reporting they were performing pelvic floor exercises 
(compared to the control groups) in both trials, it did not result in better short or medium term 
continence rates or quality of life.  It was significantly more costly to the NHS.  Hence, 
provision of one-to-one PFMT was not cost-effective for UI after either radical prostatectomy 
or TURP in the UK health care context, where advice to perform pelvic floor exercises is 
widely available through other less intensive channels, such as verbally, in leaflets or via 
internet.   
 
 
Stress urinary incontinence was more common after radical prostatectomy and urgency 
incontinence more common after TURP (Table 1).  We treated the two populations as 
separate trials because of these clinical differences.  Nevertheless, we did not find evidence 
of benefit of the intervention for either clinical group.   
 
Strengths and weaknesses 
The findings were consistent and robust.  Validated outcome measures were used to assess 
men’s subjective report of UI and pad use:  arguably, these subjective outcomes are most 
relevant to men.(11)   Independent of the statistical methods used to compare the groups, all 
the outcome measures concurred in failing to find clinically or statistically significant 
differences between the randomised groups in each trial.  Where statistically significant 
differences in costs were identified, these were due to the higher cost of providing the 
intervention rather than any consequences of the intervention.   
 
The randomised groups were comparable at trial entry on clinical and demographic 
characteristics (Table 1).  The radical prostatectomy trial (Trial 1) included 87% (411/472) of 
the men who were still incontinent six weeks later and therefore eligible to be randomised.  
Similarly, the TURP trial (Trial 2) included 86% (442/512) of the men still eligible.  These 
high participation rates, and the large number of UK centres contributing participants, 
suggest that the findings are generalisable to men with UI after radical prostatectomy or 
TURP in settings where information on PFMT is already available and accessed by men.    
 
All men were analysed in the groups to which they were randomised.  Once randomised, 
participants were compliant in attending treatment and in returning their questionnaires, 
while the withdrawal rates were low.  There was little evidence of systematic differential 
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dropout from the randomised groups (Figures 1a and b), and incontinence rates remained 
similar even if the men lost to follow up were all assumed to be dry.  This provided 
reassurance that the outcome data were representative of the men included in the trials, and 
that bias from differential attrition was minimal.  We chose not to use objective measures of 
incontinence, such as pad tests, because of practical difficulties but, more importantly, 
because we felt that the men’s rating of their incontinence was the more important clinical 
outcome.(22)  The data entry was by clerks blinded to randomisation thus minimising 
detection bias.  It was not possible to blind men or therapists to trial allocation.  Performance 
of PFMT was reported by the men themselves in questionnaires, and thus may have been 
biased if they over-reported how many times they were expected to perform them rather 
than their actual practice.  This information could not be verified objectively but was only 
used as a measure of the effect of attendance at therapy sessions on changing behaviour.   
 
It is important to note that MAPS has not tested whether PFMT itself is an effective and 
efficient way of reducing incontinence in men.  In the current health care system where 
information about incontinence after prostatectomy and PFMT is freely available, it would not 
be possible to identify a control group which was unaware of pelvic floor exercises.   
 
The methods of the economic analysis were rigorous and reproducible.  Although not 
reported in full here, we assessed the importance of uncertainties surrounding estimates of 
costs, effects and cost-effectiveness, and the conclusions were robust to these.   
 
Meaning of the study 
Despite the men’s high attendance rate at therapy visits and self-reported adherence to 
performance of PFMT at home, there was no corresponding difference in UI rates in either 
clinical group.  In contexts where advice to men about PFM exercise is widely available, this 
may be sufficient to instruct men in PFMT and adopt other behaviours aimed at improving 
their post-surgery continence.  This trial found no extra benefit from the provision of one-to-
one sessions with a therapist focusing on pelvic floor exercises and other aspects of 
conservative care such as BT and lifestyle advice for incontinent men after radical 
prostatectomy or TURP.  There was also no evidence to suggest a different conclusion in 
sub-groups of men, such as those with pre-surgery incontinence, different types of 
incontinence or those receiving PFMT from a trained continence nurse rather than a trained 
physiotherapist (Figure 4).   
 
The frequency of delivery of the intervention (four times in three months combined with 
home exercises) is typical of standard care in the NHS, and most men attended for the 
whole 3-month therapy period (Table 4).  While other trials have used different frequencies 
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of contact with therapists after surgery, ranging from five sessions over 16 weeks (23), to 
three times a week for three weeks (24), to weekly as long as the incontinence persisted 
(25), there is little evidence that more frequent contacts in men would result in better 
incontinence outcomes.(9)  However, the aim of therapy in all trials is to teach and motivate 
the men to perform pelvic floor exercises every day:  MAPS showed that this was successful 
in both trials (128/191, 67% performing them in Trial 1, and 122/188, 65% in Trial 2, 
compared with 95/189, 50% and 39/193, 20% in the respective control groups, Table 2).  
The timing of the intervention (starting six weeks postoperatively) was dictated by the terms 
of the HTA commissioning brief, but it could be argued that starting earlier or before surgery 
would result in unnecessary treatment of men who would become dry spontaneously.   
 
Before randomisation, there were considerably fewer men in the control group in the TURP 
trial performing PFMT compared to amongst the men after radical prostatectomy.  This 
probably reflects the information supplied to men and the attitudes of staff around the time of 
prostate surgery.  The underlying risk of becoming incontinent was much lower in the TURP 
group, so it may be that health professionals were less likely to recommend PFMT to men 
after TURP and indeed only around 40% (183/442) of men were aware of them, compared 
to  over 90% (380/411) of men after radical prostatectomy.  As a result, men in the Radical 
group were four times more likely to be actually performing PFMT before randomisation.  
The type of incontinence may also have affected the chance of men performing PFMT:  this 
is recommended for stress urinary incontinence but men after TURP were more likely to 
have urgency urinary incontinence (Table 1).  However, interestingly, the men in the 
intervention groups in both trials were equally likely to report that they were still performing 
PFMT at 12 months (around 65%).   
 
We have only limited information about putative mechanisms for any effects of the 
intervention through men’s reports of performing exercises and their daily frequency.  
Although we did see differential effects on these, the intervention might also be expected to 
have wider effects, such as improving the quality rather than the quantity of pelvic floor 
muscle contractions, the use of broader behavioural techniques such as BT, and generic 
quality of life, which were not measured directly.   
The incontinence rates extrapolated to the original populations of men having prostatectomy 
(20% severe after radical prostatectomy and 10% after TURP) concur with those reported in 
recent surveys of quality of life after radical prostatectomy(4;5) and the 9% reported in a 
meta-analysis of RCTs of TURP compared with alternative surgical treatments for BPE.(1)   
 
Conclusions 
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In settings where information about pelvic floor exercises is widely available, the provision of 
one-to-one conservative therapy for men with UI after radical prostatectomy or TURP is 
unlikely to be effective or cost-effective.  Resources currently allocated to providing such a 
service might be better used elsewhere.   
 
Research is needed to identify the best management for the large numbers of men who are 
left with persistent severe incontinence after radical prostatectomy, particularly the place of 
continence surgery for men.  Similarly, research is needed to identify the best management 
for men with persistent incontinence following TURP.   
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Research in Context 
 
Systematic Review Panel:   
The trial was commissioned because a Cochrane review in 1999 concluded that there was 
no reliable evidence on which to base treatment.  The most recent update of this review (9) 
found six relevant RCTs but was still inconclusive, and only one trial (26) provided 12-month 
outcomes.  The addition of MAPS to this review resulted in a Risk Ratio for urinary 
incontinence at 12 months of 0.97, 95% CI 0.87 to 1.09.  A subsequent search of the 
Cochrane Incontinence Review group’s register of trials found one more small trial (27) that 
provided outcomes at 12 months, but it had unexplained differential dropout from the control 
group.  The addition of this trial introduced significant heterogeneity and widened the 
confidence interval (RR 0.92, 95% CI 0.81 to 1.03).  
 
 
Interpretation Panel:   
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MAPS is the largest trial of formal one-to-one PFMT amongst men with urinary incontinence 
after radical prostatectomy, and the only trial in men incontinent after TURP.  Of two other 
trials after radical prostatectomy, the results of one (26) were consistent with MAPS with 
similar rates of incontinence in the two trials groups at 12 months; the other smaller trial (27) 
showed lower rates of incontinence in the PFMT group but with high differential loss to 
follow-up.   
 
 
  18 
 
Contributions of Authors 
Professor Cathryn Glazener (Professor of Health Services Research, Chief Investigator), 
was the chief investigator of the study: she had complete involvement and oversight of the 
study design, execution and data collection, and was responsible for the writing of the final 
report.   
Mr Charles Boachie (Statistician, statistical analysis) contributed to the statistical analysis of 
the study and writing of the results and discussion chapters.   
Dr Brian Buckley (Chairman, Bladder and Bowel Foundation, consumer representative) 
contributed to the consumer aspect of the study and writing the final report.   
Mrs Claire Cochran (Trial Manager) was responsible for the day to day management of the 
study and also contributed to the final report writing.   
Professor Grace Dorey (Professor, The University of the West of England, intervention 
specialist) contributed to the design of the intervention component of the study, and was also 
responsible for training the therapists recruited to provide the intervention to study 
participants.   
Professor Adrian Grant (Director of Research, trialist) contributed to the overall study design 
and gave expert guidance on the final report writing.   
Professor Suzanne Hagen (Programme Director, trial design) contributed to the design of 
the study and also to the choice and design of the outcomes measures.   
Miss Mary Kilonzo (Research Fellow, health economics) contributed to the analysis of the 
health economics component of the study and also to the writing of the health economics 
chapters.   
Mrs Alison McDonald (Senior Trial Manager, trialist) contributed to the design of the study, 
organised the authorisation of the study and contributed to the writing of the final report.    
Mrs Gladys McPherson (Senior IT Manager, programming) designed the programming of the 
study database, data analysis and writing of the final report.   
Professor Katherine Moore (Vice Dean, trialist and therapist perspective) contributed to the 
design of the therapy intervention and to the writing of the final report.   
  19 
 
Professor John Norrie (Director of ChaRT) contributed to the design, running and 
interpretation of the study,  
Dr Craig Ramsay (Healthcare Assessment Programme Director, HSRU, statistical analysis) 
contributed to the statistical analysis of the study and also to the writing of the results 
chapters.   
Professor Luke Vale (Professor of Health Technology Assessment, HERU, health 
economics) contributed to the writing of the health economics chapters and to the 
interpretation of the health economics findings.   
Professor James N’Dow (Professor of Urology, clinician) contributed his clinical expertise to 
the design of the study and to the final report writing.  
  20 
 
 
Table 1 Characteristics of the groups at trial entry after Radical Prostatectomy and TURP 
 Trial 1 Radical prostatectomy Trial 2 TURP 
 Intervent. N=205 Control N=206 Intervent. N=220 Control N=222 
Time of randomisation after surgery (weeks) 
Mean (SD) n 
7.8 (2.4) 205 8.1(2.9) 206 8.1(3.1) 220 8.6 (3.5) 222 
Age in years 
Mean, (SD) n [MIN, MAX]  
62.4 (5.8) 205 
[47, 76]  
62.3 (5.6) 206 
[47, 75] 
68.2 (7.7) 220 
[47, 90] 
67.9 (8.1) 222 
[45, 86] 
BMI,  
Mean (SD) n [Min, Max] 
25.9 (2.9) 197 
[19.4, 39.5] 
26.3 (3.3) 202 
[18.0, 36.2] 
27.1 (4.1) 217 
[15, 48] 
27.1 (4.7) 215 
[17, 44] 
TURP before index surgery n/N (%) 12/205 (6) 4/201 (2) 23/217 (11) 26/218 (12) 
Number of men not able to achieve erection 
before prostate surgery n/N (%) 
17/205 (8) 18/202 (9) 67/214 (31) 71/215 (33) 
Leakage of urine before prostate surgery 14/205 (7) 13/206 (6) 95/195 (49) 102/205 (50) 
ICIQ Score b Mean (SD) n 11.2 (4.3) 205 11.5 (4.5) 206  8.6 (4.1) 219 8.7 (4.3) 222 
Number of men with severe incontinence  
n/N (%) c 
188/205 (92) 189/206 (92) 145/220 (66) 144/222 (65) 
Number of men using pads n/N (%) 180/205 (88) 176/205 (86) 71/220 (32) 70/217 (32) 
Urinary frequency (per day) Mean (SD) n 7.4 (2.9) 187 7.9 (3.7) 192  8.6 (5.2) 205  7.9 (3.1) 199 
Urinary frequency (per night) Mean (SD) n 2.2 (1.2) 199 2.5 (1.6) 202 2.7 (1.6) 215  2.5 (1.5) 212 
     
Number of men reporting carrying out any pelvic 176/205 (86) 170/206 (83) 47/220 (21) 46/222 (21) 
15 
  21 
 
 
floor exercises before randomisation 
EQ-5D Mean (SD) n 0.8 (0.2) 200 0.8 (0.2) 206 0.8 (0.3) 213  0.8 (0.3) 213 
SF-12 Mental Mean (SD) n 50.8 (10.5) 201 49.3 (10.7) 201 49.9 (10.4) 216 50.3 (10.4) 212 
SF-12 Physical Mean (SD) n 42.7 (9.9) 201 41.8 (10.6) 201  42.7 (11.0) 216 43.2 (11.9) 212 
Type of incontinence n/N (%)     
 SUI  195/205 (95) 195/206 (95) 148/220 (67) 136/222 (61) 
 UUI  135/205 (66) 156/206 (76) 186/220 (85) 183/222 (82) 
 MUI (both) 132/205 (64) 151/206 (73) 129/220 (59) 112/222 (50) 
 Post-micturition leakage 166/205 (81) 170/206 (83) 151/220 (69) 156/222 (70) 
 Other type of incontinence 72/205 (35) 91/206 (44) 57/220 (26) 44/222 (20) 
Type of operation  Radical prostatectomy n/N (%)  
a 
Type of operation TURP n/N (%) 
 204 205  220 222 
 Abdominal  157/204 (77) 161/205 (79)  Standard TURP  210/220 (95) 207/222 (93) 
 Perineal  6/204 (3) 4/205 (2)  Laser TURP e 10/220 (5) 15/222 (7) 
 Laparoscopic d 41/204 (20) 40/205 (20)    
a Information missing in 2 cases 
b ICIQ Score:  0=none, 21 = maximum (worst) score 
c Severe incontinence defined as at least once a day AND a moderate or large amount of leakage on ICIQ-UI SF.(11)  
d No procedures were performed robotically 
e No procedures involved holmium enucleation (HoLEP) 
Numbers as reported.  SUI = Stress Urinary Incontinence.  UUI = Urgency Urinary Incontinence.  MUI = Mixed Urinary Incontinence.   
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Table 2  Outcomes at 12 months 
 Trial 1 Radical prostatectomy Trial 2 TURP 
 Intervent. 
N=205 
Control 
N=206 
RR or MD [95% CI]  
p-value 
Intervent. 
N=220 
Control 
N=222 
RR or MD [95% CI]  
p-value 
Incontinence outcomes       
Men with any 
incontinence a 
n/N (%) 
148/196 (76) 151/195 (77) 0.97 [0.87 to 1.09]  
0.64 
126/194 (65) 125/203 (62) 1.06 [0.91 to 1.23]  
0.47 
Men with severe 
incontinence b  
n/N (%) 
74/196 (38) 78/195 (40) 0.93 [0.73 to 1.19]  
0.58 
48/194 (25) 49/203 (24) 1.03 [0.73 to 1.45]  
0.88 
ICIQ Score at 12 
months c  
Mean (SD) n 
4.9 (4.1) 196 5.4 (4.5) 195 -0.34 [-1.05 to 0.38]  
0.36 
3.9 (3.7) 194 4.0 (4.3) 203 -0.04 [-0.78 to 0.71]  
0.93 
Number of men 
using pads  
n/N (%) 
63/196 (32) 68/195 (35) 0.91 [0.69 to 1.20]  
0.50 
24/194 (12) 24/203 (12) 1.05 [0.62 to 1.78]  
0.86 
Daytime urinary 
incontinence 
episodes from 
diaries 
1.7 (3.3) 183 1.7 (2.7) 181 0.04 [-0.65 to 0.72]  
0.92 
1.4 (2.3) 175 1.2 (2.2) 179 0.21 [-0.30 to 0.72]  
0.42 
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Mean (SD) n 
Nocturnal urinary 
incontinence 
episodes from 
diaries 
Mean (SD) n 
0.2 (0.6) 183 0.2 (0.8) 181 -0.05 [-0.27 to 0.16] 0.62 0.4 (0.9), 175 0.4 (0.9) 179 0.03 [-0.25 to 0.32]  
0.81 
       
Type of 
incontinence  
n/N (%) 
      
 SUI  138/196 (70) 128/195 (66) 1.071 [0.94 to 1.22] 0.31 71/194 (37) 76/203 (37) 0.91 [0.72 to 1.17] 0.48 
 UUI  61/196 (31) 83/195 (43) 0.782 [0.61 to 1.00] 0.05 72/194 (37) 82/203 (40) 0.92 [0.72 to 1.17] 0.48 
 MUI (both) 59/196 (30) 74/195 (38) 0.843 [0.65 to 1.10] 0.21 46/194 (24) 58/203 (29) 0.77 [0.56 to 1.06] 0.12 
 Post-
micturition leakage 
102/196 (52) 106/195 (54) 0.924 [0.73 to 1.17] 0.51 92/194 (47) 87/203 (43) 1.13 [0.92 to 1.39] 0.25 
 Other type 
of incontinence 
39/196 (20) 39/195 (20) 1.099 [0.74 to 1.63] 0.64 18/194 (9) 17/203 (8) 1.04 [0.55 to 1.95] 0.91 
       
Urinary frequency 
(per day)  
Mean (SD) n 
6.8 (2.1) 184 7.0 (2.8) 183 -0.24 [-0.73 to 0.26] 0.35  7.0 (4.3) 177 6.5 (2.1) 178 0.35 [-0.40 to 1.09] 0.36 
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Urinary frequency 
(per night)  
Mean (SD) n 
 1.3 (1.0) 180 1.4 (1.0) 185 -0.04 [-0.21 to 0.14] 0.68 1.7 (1.4) 177 1.8 (1.6) 181 -0.05 [-0.30 to 0.20] 0.70 
Number of men 
reporting carrying 
out any pelvic floor 
exercises n/N (%) 
128/191 (67) 95/189 (50) 1.30 [1.09 to 1.53] 0.0027 122/188 (65) 39/193 (20) 3.20 [2.37 to 4.32] 0.0001 
Number of men 
reporting carrying 
out PFMT every 
day n/N (%) 
67/192 (35) 
 
51/190 (27) 
 
 
0.85 [0.67 to 1.07]  
0.17 
51/188 (27) 
 
15/193 (8) 
 
0.90 [0.86 to 0.93] 0.0001  
 
Number of 
contractions per 
day  
Mean (SD) n 
12 (20) 191 19 (79) 189 -7.80 [-19.43 to 3.901]  
0.19 
11 (23) 188 4 (16)193 6.88 [2.91 to -10.86] 
0.0007  
 
 
      
Number of men 
with faecal 
incontinence  
n/N (%) 
16/193 (8) 11/193 (6) 1.56 [0.74 to 3.29]  
0.24 
40/192 (21) 36/199 (18) 1.06 [0.74 to 1.52]  
0.75 
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Number of men 
unable to achieve 
any erection 12 
months after 
prostate surgeryd 
n/N (%) 
105/189 (56) 105/190 (55) 0.99 [0.83 to 1.19]  
0.95 
52/177 (29) 43/178 (24) 0.82 [0.58 to 1.16]  
0.27 
EQ-5D  
Mean (SD) n 
0.879 (0.209) 
187 
0.887 (0.176) 
189 
-0.013 [-0.047 to 0.021] 
0.46 
0.784 (0.249) 
177 
0.791 (0.266) 
189 
-0.005 [-0.040 to 0.031] 
0.79 
SF-12 Mental 
Mean (SD) n 
 52.9 (9.1) 
190 
 53.6 (7.9) 
191 
-0.9 [-2.6 to 0.9]  
0.32 
52.6 (9.2)  
188 
51.7 (10.5) 
193 
-0.039 [-1.708 to 1.630] 
0.96 
SF-12 Physical 
Mean (SD) n 
 51.4 (8.3) 
190 
 51.2 (8.4) 
191 
0.0 [-1.6 to 1.6]  
0.97 
44.5 (11.1) 
188 
44.0 (13.3) 
193 
0.385 [-1.216 to 1.986] 
0.64 
       
a Incontinence defined as any positive response to either:  (1) How often do you leak urine?  or (2) How much urine do you usually leak 
(whether you wear protection or not)?  Derived from ICIQ-UI SF questionnaire.(11) 
b  Severe incontinence defined as at least once a day AND a moderate or large amount of leakage, as defined by the men in responses to 
these two questions derived from ICIQ-UI SF questionnaire.(11) 
c ICIQ Score derived from the sum of the first three questions in the ICIQ-UI SF questionnaire.(11) 
d Defined as: ‘no erection possible’.   
Numbers as reported.  Data from postal questionnaires unless otherwise indicated.   
Effect size is Mean Difference (MD) or Risk Ratio (RR) adjusted for age, urinary incontinence before surgery and baseline values 
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Table 3 Primary outcome, urinary incontinence at 12 months:  further statistical analyses 
 Trial 1 Radical prostatectomy Trial 2 TURP 
Urinary incontinence at 12 months  
n/N (%) 
Absolute Risk Difference [95% CI] 
148/196 (75.5%, intervention)  
151/195 (77.4%, control) 
-1.9% [-10% to 6%] 
126/194 (64.9%, intervention) 
125/203 (61.5%, control) 
3.4% [-6% to 13%] 
 
 
 
Risk Ratio [95% CI] p-value 
 
Risk Ratio [95% CI] p-value 
Intention to treat 
Unadjusted analysis 
 
0.98 [0.88 to 1.09] 0.72 
 
1.05 [0.91 to 1.22] 0.49 
Analysis adjusted for minimisation 
factors a 
0.97 [0.87 to 1.09] 0.64 1.06 [0.91 to 1.23] 0.47 
Adjusted treatment received b   
Unadjusted analysis 0.98 [0.88 to1.09] 0.70 1.05 [0.90 to 1.22] 0.55 
Analysis adjusted for minimisation 
factors a 
0.98 [0.88  to 1.09] 0.68 1.05 [0.90 to 1.22] 0.54 
a Minimisation factors:  age; pre-existing urinary incontinence 
b Adjusted treatment received analysis, adjusted for actual attendance (compliance) with therapy 
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Table 4  Number of therapy visits attended by men randomised to the intervention groups 
 
 First visit Second visit  Third visit Fourth visit 
RADICAL(N=205)       
Number of men attending 189 (92%) 186 (91%) 177 (86%) 175 (85%) 
TURP (N=220)     
Number of men attending 189 (86%) 173 (79%) 163 (74%) 158 (72%) 
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Figure 1a Flow Diagram Trial 1: Radical prostatectomy 
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a Postrandomisation exclusion Therapy was not available during some of the period 
of screening in one centre (18 men) 
Reasons for withdrawal after 
randomisation (Int / Control) 
Illness (1 / 1) 
Dry (1 / 1) 
No reason or other reason (3 / 2) 
  29 
 
Figure 1b Flow Diagram Trial 2:  TURP  
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Figure 2 Percentage of men incontinent and the severity* of the 
incontinence at each time point  
2a: Trial 1 Radical prostatectomy 
 
Severe incontinence is defined as at least once a day AND a moderate or large 
amount of leakage.  Int = Intervention group, Con = Control group 
2b:  Trial TURP 
 
Severe incontinence is defined as at least once a day AND a moderate or large 
amount of leakage.  Int = Intervention group, Con = Control group 
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Figure 3 Mean ICIQ Score (+/- SD) at each time point (a higher score = 
worse incontinence or effect on quality of life)  
 
3a: Trial 1 Radical prostatectomy 
   
 
3b: Trial 2 TURP 
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Figure 4  Forest plot of sub group analyses:  Urinary Incontinence at 12 
months  
 
4a: Trial 1 Radical prostatectomy 
Overall effect = 0.98, 95% CI [0.88 to 1.09], represented by broken line.  
4b: Trial 2 TURP 
 
Overall effect = 1.05, 95% CI [0.91 to 1.22], represented by broken line.  
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Explanatory footnote (for Figure 4): 
Leak Before = urinary incontinence before surgery 
Stress UI = stress urinary incontinence at randomisation after surgery 
Urge UI = urgency urinary incontinence at randomisation after surgery 
Mixed UI = both stress and urgency urinary incontinence after surgery 
PML = post-micturition leakage at randomisation after surgery 
Other morbidity = participant with other health problems at randomisation 
Physiotherapist / Nurse = professional background of therapist delivering intervention 
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